Multidomain Approaches to Prevent Cognitive Decline

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the complexity of multidomain prevention trials. The speaker systematically reviews major trials, highlighting both positive and negative results, and discusses methodological challenges such as population selection, adherence, and the need for long-term follow-up. The argumentation is well-structured and evidence-based, drawing on the speaker’s extensive experience. She acknowledges potential biases and limitations, such as the difficulty of maintaining behavior change and the possibility of practice effects. The discussion of future directions, including the use of biomarkers and biological age, is forward-looking and relevant.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor by referencing specific trials (e.g., FINGER, preDIVA, SMART) and discussing their designs and outcomes. The speaker mentions a systematic review of 29 trials, indicating a comprehensive approach. The title accurately reflects the content. The speaker discloses her involvement in large trials, which is transparent. The talk is part of a symposium on exposomics and brain health, and the description lists funding sources, adding credibility. No specific sources are cited in the video, but the description provides context and funding information.

The title accurately reflects the content, which focuses on multidomain interventions to prevent cognitive decline.

8/10

Presentation by a leading expert in dementia prevention trials, based on a systematic review of 29 randomized controlled trials and personal experience. The speaker discloses potential bias and discusses methodological challenges. The content is consistent with current scientific literature, though it reflects the author's perspective.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction and disclosure of involvement in large clinical trials.
• 05:00Discussion of why most preventive trials are negative.
• 10:00Overview of 29 multidomain trials and key positive trials like FINGER.
• 15:00Challenges in recruitment and adherence, including findings from the MAPT trial.
• 20:00Discussion of future directions: larger trials, biomarkers, and surrogates.
• 25:00Q&A session on trial design and implementation.

• FINGER trial — Referenced as a landmark multidomain trial with positive results.
• preDIVA study — Mentioned as a negative trial with over 3,000 participants.
• SMART trial — Discussed as a personalized intervention with positive results.
• Maintain Your Brain study — Online intervention trial with positive cognitive outcomes.
• APPLE-Tree trial — Online trial with low intensity that missed primary endpoint.

• Lancet Commission on dementia prevention — Supports the importance of modifiable risk factors.
• FINGER trial publication — Positive results align with the speaker's emphasis on multidomain interventions.

• preDIVA study — Negative result despite large sample and long follow-up, contrasting with positive trials.